Advertisement

ASCO Daily News

Top Stories

Bevacizumab or Cetuximab with FOLFOX or FOLFIRI Offer Similar, Extended Survival in Metastatic Colorectal Cancer



ALTTO Trial Findings Raise Questions on Approach to Drug Development in Early Breast Cancer


Durable Responses to Ibrutinib Seen in Patients with Chronic Lymphocytic Leukemia


Extraordinary Responders Drive Concept of Basket Trial Design



No Benefit Seen with Cetuximab Addition in Patients with mCRC, RAS-Activating Mutation